Skip to main content
TYK Medicines, Inc logo

TYK Medicines, Inc — Investor Relations & Filings

Ticker · 2410 ISIN · CNE100006L34 HKEX Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2024-09-05 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2410

About TYK Medicines, Inc

https://www.tykmedicines.com

TYK Medicines, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative small-molecule targeted therapies. The company leverages a proprietary small molecule drug design and screening platform, with a primary strategic focus on oncology, particularly treatments for lung cancer. The lead pipeline asset, TY-9591 (Edotamidine mesylate), an EGFR-targeted therapy, is currently in the Pre-NDA stage, having demonstrated promising clinical efficacy in treating lung cancer patients with brain metastasis. The pipeline also includes assets such as TY-302 and TY-2136, alongside multiple CDK inhibitors in clinical development, reflecting a commitment to addressing unmet medical needs in targeted cancer treatment.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2024
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on the registered share capital, issued shares, and treasury shares of TYK Medicines, Inc. It includes tables showing balances at the beginning and end of the month, confirms no changes in share capital or treasury shares, and notes the listing date on the Hong Kong Stock Exchange. The document is titled as a "Monthly Return for Equity Issuer and Hong Kong Depositary Receipts" and is addressed to the Hong Kong Exchanges and Clearing Limited. It does not contain financial statements, earnings data, management discussion, or audit information. Instead, it reports on share capital and share movements, which aligns with announcements related to share capital changes or share issues. Given the detailed nature of share capital and share movement data, and the absence of financial results or management commentary, the document fits best under the category of Share Issue/Capital Change (SHA). The document length (6471 characters) and content confirm it is a substantive report, not merely an announcement of a report or a certification. Therefore, the classification is SHA with high confidence.
2024-09-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
Regulatory Filings Classification · 95% confidence The document is a monthly return report for an equity issuer and Hong Kong Depositary Receipts under Chapter 19B of the Exchange Listing Rules, detailing movements in securities for the month ended 31 August 2024. It includes information on issued shares, treasury shares, share options, warrants, convertibles, and confirmations. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share movements. It is not an annual or interim financial report, nor an earnings release or management discussion. It is a regulatory filing reporting share capital movements and confirmations, fitting best under the category of Regulatory Filings (RNS). The document length is under 5,000 characters and is a formal regulatory submission rather than a report publication announcement or a financial report itself.
2024-09-02 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024' and contains detailed unaudited condensed consolidated interim financial statements including profit or loss, financial position, notes to the interim financial statements, and management discussion and analysis. It covers a six-month period ending June 30, 2024, and includes substantive financial data and analysis. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. The content aligns with the characteristics of an Interim / Quarterly Report (IR) as it provides comprehensive financial information for a period shorter than a full fiscal year. Therefore, the appropriate classification is IR. H1 2024
2024-08-30 English
CLARIFICATION ANNOUNCEMENT
Capital/Financing Update Classification · 95% confidence The document is an announcement related to the final offer price and allotment results of a share offering by TYK Medicines, Inc. It includes detailed information about the number of shares offered, subscription levels, cornerstone investors, lock-up undertakings, and clarifications to a previous announcement. The content focuses on the pricing and allocation of shares in a public and international offering, which is typical of capital raising activities. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a proxy statement, AGM material, or management discussion. The document is clearly an update on the company's capital raising and share issuance process, including offer price and allotment results. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2024-08-23 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from TYK Medicines, Inc. regarding the date of a Board meeting scheduled for August 30, 2024. The purpose of the meeting is to consider and approve the interim results for the six months ended June 30, 2024, and to consider the payment of an interim dividend. The document does not contain any financial data or the actual interim results; it only announces the upcoming board meeting and the agenda. The document length is short (1672 characters) and it is clearly an announcement rather than a report. According to the classification rules, announcements about upcoming board meetings and agenda items fall under Regulatory Filings (RNS) as they do not contain substantive financial data or the report itself. Therefore, the correct classification is Regulatory Filings (RNS).
2024-08-20 English
ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS
Capital/Financing Update Classification · 95% confidence The document is an announcement detailing the final offer price and allotment results for a company's public and international share offering. It includes information on the number of shares offered, subscription levels, lock-up undertakings, cornerstone investors, and proceeds from the offering. This type of document is related to the company's capital raising activities and share issuance rather than a financial report, management discussion, or regulatory filing. It is not an annual or interim report, earnings release, or governance information. The content clearly fits the category of a Capital/Financing Update, as it provides detailed information about the company's fundraising and share capital changes associated with the public offering.
2024-08-19 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.